Win 'Won't Move Needle Much'
Tarceva Reprieve? FDA Delay Could Mean Little Either Way
By Randy Osborne
Monday, January 25, 2010
Last week's Tarceva news - unlike the thumbs-down vote by an FDA advisory panel in December - came as little surprise: The action date for a decision on the already-marketed EGFR drug in a new indication, first-line maintenance therapy for non-small-cell lung cancer, has been set back 90 days to April 18.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.